Aquestive Therapeutics (AQST) Operating Income (2017 - 2025)
Historic Operating Income for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to -$11.5 million.
- Aquestive Therapeutics' Operating Income fell 3846.8% to -$11.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$55.8 million, marking a year-over-year decrease of 16437.47%. This contributed to the annual value of -$30.8 million for FY2024, which is 10375.45% down from last year.
- Per Aquestive Therapeutics' latest filing, its Operating Income stood at -$11.5 million for Q3 2025, which was down 3846.8% from -$11.4 million recorded in Q2 2025.
- In the past 5 years, Aquestive Therapeutics' Operating Income registered a high of $55000.0 during Q2 2024, and its lowest value of -$19.4 million during Q1 2025.
- For the 5-year period, Aquestive Therapeutics' Operating Income averaged around -$8.7 million, with its median value being -$8.9 million (2022).
- Per our database at Business Quant, Aquestive Therapeutics' Operating Income surged by 10130.67% in 2024 and then crashed by 2076909.09% in 2025.
- Aquestive Therapeutics' Operating Income (Quarter) stood at -$11.7 million in 2021, then rose by 8.19% to -$10.7 million in 2022, then skyrocketed by 63.49% to -$3.9 million in 2023, then tumbled by 247.2% to -$13.6 million in 2024, then grew by 15.47% to -$11.5 million in 2025.
- Its Operating Income was -$11.5 million in Q3 2025, compared to -$11.4 million in Q2 2025 and -$19.4 million in Q1 2025.